Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20371518 | 0.86 | SORD (0.34) | — | |
| SCHEMBL18950388 | 0.81 | APLNR (0.35) | APLNR | |
| SCHEMBL19919582 | 0.76 | APLNR (0.36) | APLNR | |
| SCHEMBL830187 | 0.71 | CYP1A2 (0.37) | — | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.69 | CYP1A2 (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.68 | CYP1A2 (0.35) | — | |
| SCHEMBL22395438 | 0.67 | APLNR (0.50) | APLNR | |
| SCHEMBL19123072 | 0.67 | APLNR (0.50) | APLNR | |
| SCHEMBL25888171 | 0.67 | SORD (0.38) | — | |
| SCHEMBL23015778 | 0.67 | TRPV3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | APLNR 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.